Throughout its history, the United States has led the world in protecting intellectual property (IP) rights. On that foundation, we have also led the world in artistic, commercial, and scientific innovation, particularly with life-saving medicines and vaccines.
Yet patent rights are under increasing assault, with anti-patent activists charging pharmaceutical makers with “antitrust” violations for utilizing and building upon their patents for the greater good. Their rhetoric and false critiques under the guise of “antitrust” typically rely upon an array of misleading and pejorative labels, to the point where they take on a meaning that bears no resemblance to reality.
Join Gene Quinn, President, and CEO of IPWatchdog, Inc., for a free webinar conversation that will debunk the myths associated with patent thickets and pejorative terms used to denigrate innovators and patent owners. Joining Gene will be Timothy Lee, SVP of Legal Affairs, for the Center for Individual Freedom, Chris Israel, Executive Director for the Alliance of U.S. Startups for Inventors and Jobs, Andrew Spiegel, Executive Director for the Global Colon Cancer Association, and Adam Mossoff, Antonin Scalia Law School, George Mason University and Senior Fellow and Chair of the Forum for IP, Hudson Institute.
During the webinar the panel will discuss:
- The important role innovators play in the technology economy;
- Why so-called “patent thickets” actually increase innovation;
- Why claims of “product hopping” are not about pharmaceutical coercion but instead are about preventing follow-on pharmaceutical innovation so generics can compete with the drug being sold by brand name pharma companies;
- Why courts have ruled “pay-for-delay settlements” are a valid by-product of a patent holder’s exclusionary rights.